-
- Dexcom G7 15 Day* is now cleared in the US for people age 18 years and above with diabetes.
- Now the longest lasting*,†,1 and most accurate1 CGM system, Dexcom G7 15 Day gives users the knowledge to better control diabetes.
- For people between the ages 2 to 18, Dexcom G7 remains the most accurate2 continuous glucose monitoring system.
Author Archive: AZBio
Fighting the fungus among us
ASU researchers use environmental factors to predict valley fever spreadContinue reading
New 3D technology paves way for next-generation eye tracking
Eye tracking plays a critical role in the latest virtual and augmented reality headsets and is an important technology in the entertainment industry, scientific research, medical and behavioral sciences, automotive driving assistance and industrial engineering. Tracking the movements of the human eye with high accuracy, however, is a daunting challenge.Continue reading
ABOR Confirms the Appointment of Janko Nikolich as a Regents Professor
Regents Professor is the highest faculty rank at the University of Arizona, awarded to full professors whose exceptional achievements warrant national and international distinction. Appointments to this rank are limited to no more than 3% of the university’s tenured and tenure-track faculty members.Continue reading
Picard Medical Plans IPO on the NYSE
Picard Medical, Inc. is a holding company that owns 100% of the membership interests of SynCardia Systems, LLC (“SynCardia”). A medical technology company based in Tucson, AZ, SynCardia manufactures and sells the only U.S. Food and Drug Administration (“FDA”), and Health Canada approved implantable total artificial heart (the “SynCardia TAH”). To date, over 2,100 SynCardia TAHs have been implanted in patients in 27 countries and the SynCardia TAH is an established bridge to heart transplantation for patients with biventricular failure in the U.S., and around the world.
BIRD Foundation Call for Proposals – May 14 2025 Deadline
The BIRD Foundation was established by the U.S. and Israeli governments in 1977 to generate mutually beneficial cooperation between U.S. and Israeli companies, including start-ups and established organizations. BIRD provides both matchmaking support between U.S. and Israeli companies, as well as funding covering up to 50 percent of project development costs, up to $1.5M per project. BIRD takes no equity in the companies.Continue reading
ALL ALS consortium launches website to advance ALS research
Newly established clinical research consortium, led by Barrow Neurological Institute and Massachusetts General Hospital, surpasses 300 study participants
HHS Announces Restructure and Staff Reductions
“The restructuring will address this and serve multiple goals without impacting critical services. First, it will save taxpayers $1.8 billion per year through a reduction in workforce of about 10,000 full-time employees who are part of this most recent transformation. When combined with HHS’ other efforts, including early retirement and Fork in the Road, the restructuring results in a total downsizing from 82,000 to 62,000 full-time employees.”Continue reading
City of Hope-led study demystifies tumor formation’s two-step process — a foundational understanding needed to prevent cancer
Preclinical findings published in Cancer Discovery show that mutated cells can persist for years without becoming cancer and need an additional inflammatory “push” for malignancy to occurContinue reading
New survey: U.S. biotechs warn tariffs could impede access to cures, stifle innovation
WASHINGTON (March 26, 2025) — Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical supply chain. According to the findings, nearly 90% of U.S. biotech companies rely on imported components for at least half of their FDA-approved products — making the supply of medicines for US patients and families especially vulnerable to proposed tariffs on the European Union, China, and Canada.